58 results about "Insulin-like growth factor" patented technology

The invention provides a tetrapeptide for promoting bone growth, the amino acid sequence of the tetrapeptide is Glu-Pro-Gly-Phe (EPGF), the molecular weight of the tetrapeptide is 448.48 Da, the tetrapeptide can be prepared from egg yolk protein through protease enzymolysis, separation and purification and can also be obtained through chemical solid-phase synthesis, and the tetrapeptide belongs to the technical field of functional bioactive peptides. The tetrapeptide prepared by the invention can promote the growth of osteoblasts in a body and improve the secretion level of insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1) and I-type procollagen amino terminal peptide (PINP) in cells, so that the effect of promoting bone growth is achieved, and a new functional component is provided for a product for improving bone growth.

The invention provides a polypeptide capable of selectively inhibiting COX-2 and having an IGF-1 function and application of the polypeptide, and belongs to the technical field of hair growth. The invention provides a polypeptide capable of selectively inhibiting COX-2 and having an IGF-1 function. The polypeptide comprises an end-capping group, a self-assembly group and an insulin-like growth factor C structural domain polypeptide IGF-1C which are connected in sequence, the end-capping group is naproxen; the self-assembly group is gffy; the amino acid sequence of the insulin-like growth factor C structural domain polypeptide IGF-1C is GYGSSSRRAPQT (insulin-like growth factor C structural domain polypeptide). The polypeptide capable of selectively inhibiting COX-2 and having the IGF-1 function, provided by the invention, has double functions of promoting hair follicle cell proliferation and reducing the expression level of inflammatory cells COX-2 so as to regulate an immune microenvironment, and can effectively promote hair regeneration.

The invention belongs to the technical field of stem cell culture, and discloses a culture method of bone marrow mesenchymal stem cells. A culture medium added with glutathione, L-ascorbic acid, L-glutamine, human serum albumin, sodium hydrosulfide, insulin, insulin-like growth factor-1, deer bone morphogenetic protein and antler stem cell exosome extract is used for culturing the bone marrow mesenchymal stem cells, and osteogenic differentiation of the bone marrow mesenchymal stem cells can be directionally induced. The culture medium does not contain animal serum, the formula is simple, the components are controllable, the cultured bone marrow mesenchymal stem cells are high in activity and good in state, the expression of marker genes of osteogenic differentiation is up-regulated, the regulation and control efficiency and accuracy of osteogenic differentiation are remarkably improved, and sufficient cell sources are provided for scientific research and clinic.

Provided are compositions and methods useful for sensitizing a neuron to insulin or insulin-like growth factor 1 (IGF-1), wherein the neuron is resistant to either insulin or IGF-1. Also provided are compositions and method useful for inhibiting intracellular beta amyloid peptide Aβ42-mediated decrease in neuronal viability. Also provided are compositions and methods useful for improving synaptic plasticity. Also provided are compositions and methods useful for improving learning and memory. In certain embodiments, the composition comprises (Z)-5-(4-chlorophenyl)-3-phenylpent-2-enoic acid (PS48). In certain embodiments, the method comprises contacting a neuron with PS48. In certain embodiments, the method comprises administering an effective amount of PS48 to a subject in need thereof.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The invention provides an insulin-like growth factor detection method and kit based on QAMS sampling, and belongs to the technical field of protein biological detection.The insulin-like growth factor detection method comprises the steps that a quantitative absorption microsampler is used for conducting peripheral blood sample collection on a sampling object, and an equivalent dried blood spot sample is obtained; the method comprises the following steps: extracting a supernatant sample containing an insulin-like growth factor internal standard working solution through pretreatment: transferring a dried blood spot sample into a centrifugal tube or a pore plate, adding the prepared insulin-like growth factor internal standard working solution, carrying out ultrasonic treatment, adding an acetonitrile solution containing acetic acid to remove protein, carrying out normal-temperature vortex incubation, adding an ammonia water solution, and carrying out ultrasonic treatment to obtain a supernatant sample containing the insulin-like growth factor internal standard working solution; centrifuging to obtain a supernate sample, and carrying out SPE (Solid Phase Extraction) purification on the extracted supernate sample; and detecting the content of the insulin-like growth factor in the extracted and SPE-purified supernate sample by adopting liquid chromatography-mass spectrometry to obtain the concentration of the insulin-like growth factor. The detection method disclosed by the invention has the advantage of ensuring that the IGF-1 detection concentration is close to the real concentration of a sampled human body.

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.

The invention discloses a kind of bovine adipose mesenchymal stem cell serum-free culture medium suitable for cell culture meat, belongs to the field of animal cell culture technology, including DMEM basic culture, L-alanyl-L-glutamine, recombinant transferrin, recombinant bovine insulin, sodium selenite, zinc sulfate heptahydrate, cortisol, recombinant human albumin, recombinant basic fibroblast growth factor, recombinant transforming growth factor β1, recombinant insulin-like growth factor, ethanolamine, mercaptoethanol and 2-phosphoric acid-L-ascorbic acid sodium salt. The inventor of the present application has obtained a new bovine adipose-derived stem cell (Adipose-derived stem cell, ADSC) serum-free culture medium through repeated experimental verification, which can effectively culture bovine adipose mesenchymal stem cells.

The present invention relates to a probiotic agent for promoting height development containing Lactobacillus casei LC89 strain and its application. Lactobacillus cheese LC89 strain and Bifidobacterium longum subsp. infantis Bifidobacterium longum subsp.infantis The probiotics are composed of BI03 strains. In terms of growth and development indicators, they can significantly increase the weight and length of mice; in terms of bone development indicators, they can significantly increase the bone density and bone length of mice; in terms of biochemical indicators, they can significantly increase the levels of growth hormone and insulin-like growth factor-1 in mice.

Methods are provided for detecting and / or quantifying insulin-like growth factor-2 (IGF-2) variant(s) in a sample. Methods provided herein are further directed to using the detected ion or ions to determine the presence of IGF2 variant(s) in the sample.

Methods are provided for detecting insulin-like growth factor-I (IGF-I) variant(s) in a sample. Methods provided herein are further directed to using the detected ion or ions to determine the presence of IGF1 variant(s) in the sample.

The invention relates to the field of medicines, in particular to a release microsphere containing insulin-like growth factors and a macromolecular polylactic acid-glycolic acid copolymer and application of the release microsphere in skin wounds. The release microsphere (IGF-PLGA) comprises the following effective components: an insulin-like growth factor and a macromolecular polylactic acid-glycolic acid copolymer. The IGF-PLGA sustained release microspheres can slowly release IGF for a long time in vivo and in vitro; in an animal trapped flap model, compared with independent use of the IGF and IGF-PLGA sustained release microspheres, repair and healing of a mouse trapped flap can be remarkably promoted; animal skin flap tissue is extracted for HE and Masson dyeing, and it is found that the IGF-PLGA microsphere group can significantly promote granulation hyperplasia and collagen deposition; the IGF-PLGA sustained-release microsphere group can be used for effectively inhibiting the oxidative stress related protein expression of the skin flap tissue; the proliferation protein expression quantity of the IGF-PLGA group is higher than that of other groups.

A method and compositions of treatment for improving skin health and sleep quality using supplementation, comprising the step of applying a supplement formulation to a human subject via a selected administration route, the supplement formulation comprising therapeutically effective amounts of a hormone supplement, a plurality of collagen peptides, and a plurality of elastin peptides. The hormone supplement may comprise either HGH or IGF-1, or precursors or analogues thereof, and the collagen peptides may be sourced from a plurality of animal-based sources, which may include at least one of chicken bone, bovine hide, or fish tissues.

Provided in the present disclosure is a method for preparing chimeric antigen receptor cells via electroporation, which reduces electroporation damage to cells, and improves the proliferation multiple, cell activity and positive rate of the chimeric antigen receptor cells. The method comprises: contacting cells with an auxiliary agent, and then introducing a nucleic acid molecule into the cells via electroporation, wherein the auxiliary agent is insulin and / or an insulin-like growth factor.

The invention relates to the field of biological medicine, in particular to application of a small molecule compound in preparation of an anti-aging preparation. The invention provides an application of a small molecule compound in preparation of a preparation for treating and / or preventing senescence of a subject, and is characterized in that the small molecule compound comprises quinacrine and / or rimonaban. According to the present invention, both the quinacrine and the rimonabant can provide the anti-aging effect by adjusting the insulin / insulin-like growth factor (ILS) signal channel, such that the quinacrine and the rimonabant can be adopted as the novel insulin / insulin-like growth factor signal channel regulator so as to provide the life prolonging effect on the subject.

The present application belongs to the technical field of in vitro detection, and particularly relates to a quantitative detection method of IGF-1 variants. The present inventors have found that IGF-1 exists in two variant forms, namely a des-R IGF-1 variant with a single charge mass ratio of 7500-7520 and a des-RR IGF-1 variant with a single charge mass ratio of 7343-7363, and by using the detection method of the present application for the variants of insulin-like growth factor I, in particular, the creative finding that when detection is performed, IGF-1 antibodies are bonded to epoxy magnetic beads, so that the detection method can accurately detect the des-R IGF-1 variant and the des-RR IGF-1 variant, thereby providing refined data for disease analysis of IGF-1.

The invention provides AI systems that output proposed combinations of agents such as active pharmaceutical ingredients and other agents useful for a therapeutic objectives. Systems of the invention propose cocktails of those agents and optionally simulate or model effects of those agents to evaluate the potential effects of those agents in accomplishing the therapeutic objective. Specific embodiments provide a skin care composition from the AI system. The composition includes (i) a mixture of agents that includes epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin-like growth factor (IGF-1) and one or more of: a collagen-stimulating peptide, a booster of nicotinamide phospho-ribosyl-transferase (NAMPT) expression, coenzyme Q10, a nucleic acid repair enzyme, and a ceramide; (ii) one or more liposomes encapsulating at least a portion of the mixture of agents; and (iii) a moisturizer carrying the liposomes and the mixture of agents.

Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody / antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.

The invention provides a method for preparing chimeric antigen recipient cells through electroporation, which can reduce cell electroporation damage and improve the proliferation multiple, cell activity and positive rate of the chimeric antigen recipient cells, and comprises the following steps: contacting cells with an auxiliary agent, and introducing nucleic acid molecules into the cells through electroporation, the adjuvant is insulin and / or an insulin-like growth factor.

A method of determining the amount of an IGF-I and / or IGF-II protein in a sample using high resolution / high accuracy mass spectrometry includes enriching an IGF-I and / or IGF-II protein in a sample, ionizing an IGF-I and / or IGF-II protein from the sample to generate IGF-I and / or IGF-II protein ions, and determining the amount of IGF-I and / or IGF-II protein ions with high resolution / high accuracy mass spectrometry.

The present application belongs to the technical field of in-vitro detection, and particularly relates to a quantitative detection kit for insulin-like growth factor I variants. The present inventors have found that IGF-1 exists in two variant forms, namely a des-R IGF-1 variant with a single charge mass ratio of 7500-7520 and a des-RR IGF-1 variant with a single charge mass ratio of 7343-7363, and the quantitative detection kit for the variants of insulin-like growth factor I of the present application can accurately detect the des-R IGF-1 variant and the des-RR IGF-1 variant, thereby providing refined data for disease analysis of IGF-1.

The present invention relates to a polyomaviral gene delivery vector particle comprising a nucleic acid sequence encoding a phosphatase activity-possessing polypeptide. In particular the present invention relates to a polyomaviral gene delivery vector particle comprising a nucleic acid sequence encoding an alkaline phosphatase activity-possessing polypeptide, and / or further comprising a nucleic acid sequence encoding a growth factor protein, such as insulin and / or insulin-like growth factor or precursors thereof. The present invention further relates to a polyomaviral gene delivery vector particle according to the present invention for use in a method of treatment by removal or inactivation of damage-associated molecular patterns at the site of the inflammation in a subject and a composition comprising the polyomaviral gene delivery vector particle of the present invention.

The present application relates to disruption of insulin-like growth factor 2 (IGF2) secretion to treat cancer, in particular to pharmaceutical compositions and methods for inhibiting IGF2 signaling. IGF2 is a key signaling molecule that plays an important role in a variety of physiological processes, including skeletal muscle generation and adult muscle remodeling during development. Abnormal activation of the signaling pathway induced by IGF2 has been shown to promote cancer progression. A p24 family protein TMED10 plays a role of a cargo receptor, and promotes IGF2 to be output from an endoplasmic reticulum (ER) by recognizing an ER output signal on IGF2. In addition, the TMED10 also mediates the ER output of another sortilin, and the protein is very important for regulating the output of IGF2 from the reverse Golgi body net. The present application features a new therapeutic strategy for the treatment of cancer, including but not limited to inhibitors targeting the interaction between IGF2 and TMED10.

Methods are provided for determining the amount of an IGF-I and / or IGF-II protein in a sample using high resolution / high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and / or IGF-II protein in a sample, ionizing an IGF-I and / or IGF-II protein from the sample to generate IGF-I and / or IGF-II protein ions, and determining the amount of IGF-I and / or IGF-II protein ions with high resolution / high accuracy mass spectrometry.

The invention relates to the technical field of medicine, in particular to a biotinylated insulin-like growth factor-I polypeptide, a preparation method and application, the molecular formula of the biotinylated insulin-like growth factor-I polypeptide is C61H97N21O21S, and the biotinylated insulin-like growth factor-I polypeptide is obtained by blocking the N end of the amino acid sequence SEQ ID NO.1 of the insulin-like growth factor-I polypeptide with biotin. The biotinylated insulin-like growth factor-I polypeptide is prepared by adopting a classical Fmoc oligopeptide solid-phase synthesis method. The biotinylated insulin-like growth factor-I polypeptide prepared by the method is high in purity, simple to operate, good in reproducibility and capable of realizing large-scale production. The insulin-like growth factor-I polypeptide is endowed with targeting property by using biotin end capping, the stability and transdermal absorption rate of the insulin-like growth factor-I polypeptide are improved, and a good hair regeneration effect can be realized by directly applying the insulin-like growth factor-I polypeptide to the skin.

The application discloses an amplification culture medium and a culture method of human adult epidermal stem cells, and relates to the technical field of stem cell in-vitro culture. The culture medium comprises the following components: fibroblast growth factor, interleukin-6, insulin-like growth factor-1, epidermal growth factor, insulin, growth hormone, hydrocortisone, Y-27632, A83-01, Forsklin, PY60, CHIR99021, linoleic acid, linolenic acid, alanine, asparagine, glutamic acid, glycine, proline, serine, arginine, N-acetyl-L-cysteine, beta-mercaptoethanol and CaCl2. The culture medium can continuously and stably culture human adult epidermal stem cells for more than 20 generations, and a more stable long-term in-vitro amplification system of epidermal stem cells is established. After continuous subculture, the epidermal stem cells can maintain a high proliferation rate and multiple differentiation potential, and have the ability to construct multilayer skin.

To provide a pharmaceutical composition for enhancing the expression of the insulin-like growth factor 2 gene and a food composition for enhancing the expression of the insulin-like growth factor 2 gene.SOLUTION: The present invention provides a pharmaceutical composition for enhancing the expression of the insulin-like growth factor 2 gene and a food composition for enhancing the expression of the insulin-like growth factor 2 gene, containing 5-acetyl-1-benzylpyrrolidine-2-one as an active ingredient.SELECTED DRAWING: None

This invention discloses a method for processing and detecting insulin-like growth factor (IGF) in blood samples. The sample is treated with a 0.6% SDS dissociator and precipitant, and the precipitate is further washed with glacial acetonitrile to remove SDS and reduce damage to the instrument. Detection is performed using established chromatographic and mass spectrometry conditions, and a standard curve is used to determine the IGF content in the blood sample. This method does not require SPE purification, and mass spectrometry detection takes only 4.5 minutes, significantly reducing costs and detection time for large sample volume applications.

The invention relates to an insulin-like growth factor I quantitative determination kit and a preparation method thereof. Specifically, the insulin-like growth factor I detection kit comprises: 1) a lysate; 2) a reagent buffer solution; 3) coupling the anti-insulin-like growth factor I antibody with alkaline phosphatase; and 4) a biotin-labeled anti-insulin-like growth factor I antibody. The insulin-like growth factor I detection kit disclosed by the invention is good in stability, strong in specificity and good in precision.